Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a mo… Read more
Kiniksa Pharmaceuticals Ltd (KNSA) - Total Assets
Latest total assets as of September 2025: $712.33 Million USD
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) holds total assets worth $712.33 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kiniksa Pharmaceuticals Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Kiniksa Pharmaceuticals Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kiniksa Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Kiniksa Pharmaceuticals Ltd's total assets of $712.33 Million consist of 57.2% current assets and 42.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.6% |
| Accounts Receivable | $41.72 Million | 7.2% |
| Inventory | $26.36 Million | 4.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.25 Million | 2.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kiniksa Pharmaceuticals Ltd's current assets represent 57.2% of total assets in 2024, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 31.6% of total assets in 2024, down from 99.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
Kiniksa Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Kiniksa Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Kiniksa Pharmaceuticals Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Kiniksa Pharmaceuticals Ltd generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kiniksa Pharmaceuticals Ltd is currently not profitable relative to its asset base.
Kiniksa Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.85 | 3.24 | 10.46 |
| Quick Ratio | 3.51 | 2.95 | 10.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $351.94 Million | $ 215.35 Million | $ 301.40 Million |
Kiniksa Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Kiniksa Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.33 |
| Latest Market Cap to Assets Ratio | 2.85 |
| Asset Growth Rate (YoY) | 10.3% |
| Total Assets | $580.55 Million |
| Market Capitalization | $1.65 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kiniksa Pharmaceuticals Ltd's assets at a significant premium ( 2.85x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kiniksa Pharmaceuticals Ltd's assets grew by 10.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kiniksa Pharmaceuticals Ltd (2016–2024)
The table below shows the annual total assets of Kiniksa Pharmaceuticals Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $580.55 Million | +10.30% |
| 2023-12-31 | $526.32 Million | +14.50% |
| 2022-12-31 | $459.67 Million | +97.45% |
| 2021-12-31 | $232.80 Million | -33.38% |
| 2020-12-31 | $349.46 Million | +37.30% |
| 2019-12-31 | $254.53 Million | -20.94% |
| 2018-12-31 | $321.96 Million | +577.94% |
| 2017-12-31 | $47.49 Million | -15.89% |
| 2016-12-31 | $56.47 Million | -- |